Skip to main content
Premium Trial:

Request an Annual Quote

Mirna miRNA Patent Application Gets USPTO Nod


Mirna Therapeutics said this week that it has received a notice that the US Patent and Trademark Office has allowed claims within a patent application related to the therapeutic use of microRNA-34a.

According to the company, miR-34a is a potent tumor suppressor, and the patent application describes methods of reducing cancer cell viability by introducing the non-coding RNA into cancerous T cells or lung, prostate, or skin cancer cells.

Mirna is currently developing a miR-34a mimic that it expects to move into phase I testing next year (GSN 1/20/2011).

The Scan

Study Points to Tuberculosis Protection by Gaucher Disease Mutation

A mutation linked to Gaucher disease in the Ashkenazi Jewish population appears to boost Mycobacterium tuberculosis resistance in a zebrafish model of the lysosomal storage condition, a new PNAS study finds.

SpliceVault Portal Provides Look at RNA Splicing Changes Linked to Genetic Variants

The portal, described in Nature Genetics, houses variant-related messenger RNA splicing insights drawn from RNA sequencing data in nearly 335,700 samples — a set known as the 300K-RNA resource.

Automated Sequencing Pipeline Appears to Allow Rapid SARS-CoV-2 Lineage Detection in Nevada Study

Researchers in the Journal of Molecular Diagnostics describe and assess a Clear Labs Dx automated workflow, sequencing, and bioinformatic analysis method for quickly identifying SARS-CoV-2 lineages.

UK Team Presents Genetic, Epigenetic Sequencing Method

Using enzymatic DNA preparation steps, researchers in Nature Biotechnology develop a strategy for sequencing DNA, along with 5-methylcytosine and 5-hydroxymethylcytosine, on existing sequencers.